On September 23, 2026 Lōkahi Therapeutics Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), reported that Innovate GBM, a 501(c)(3) nonprofit organization dedicated to accelerating the development of new treatments for glioblastoma (GBM) and other brain tumors, has engaged two ai² PIPELINE project teams to identify and evaluate brain tumor therapeutic assets available for licensing and development. Innovate GBM is the first external organization to secure access to the Lōkahi proprietary asset identification process, which is implemented through its current 14 university collaborations. This engagement marks the ai² Division’s evolution from an internal asset discovery engine to a model capable of supporting the strategic interests of outside organizations.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The sponsorship expands the role of the ai² Division beyond Lōkahi’s own asset discovery efforts. By enabling an external organization to direct project teams toward defined areas of interest, Lōkahi is extending the platform’s analytical reach and demonstrating how the model can augment traditional business development and investment diligence.
"Innovate GBM’s engagement is the next step forward for the ai² PIPELINE as it moves the platform from a company-led initiative to a model that outside organizations can put to work," said Erik Emerson, Chief Executive Officer of Glucotrack. "This is where the concept begins to scale. We are creating a disciplined way to bring more minds, more perspectives, and more structured evaluation to the search for differentiated therapeutic opportunities."
"Glioblastoma remains one of the hardest problems in oncology, and too many promising programs have been shelved before they ever reached brain tumor patients," said Kush Thukral, JD, Co-Executive Director of Innovate GBM. "Lōkahi’s ai² PIPELINE gives us a disciplined, capital-efficient way to search systematically for overlooked brain tumor assets."
Lōkahi continues to expand ai² Division through a growing network of university collaborations. The Innovate GBM engagement adds a new dimension to that network by connecting student talent and industry expertise directly to the priorities of an external sponsor. Innovate GBM’s project teams will focus on therapeutic assets in glioblastoma and other brain tumors, and Innovate GBM will independently determine whether to pursue any asset identified. Lōkahi believes this sponsor-led model can broaden the platform’s relevance across pharmaceutical companies, biotechnology companies, and investment organizations seeking earlier visibility into differentiated opportunities.
(Press release, Lokahi Therapeutics, SEP 23, 2026, View Source [SID1234671039])